IQVIA Holdings Inc. (NYSE: IQV) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $43.6B. The Maz Rating grades it against the other companies in its sector.
IQVIA Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $264.73, IQVIA Holdings Inc. trades at 31.9x trailing earnings, 2.5x sales and 6.6x book value, with an EV/EBITDA of 16.1. Over the last twelve months it generated about $17.3B of revenue and $1.4B of net income. It runs a gross margin of 26.5%, an operating margin of 13.4% and a net margin of 8.1%. It shows return on equity of 21.8%, return on invested capital of 8.2% and a free cash flow yield of 4.8%. On the balance sheet: a debt-to-equity ratio of 2.45 and a current ratio of 0.83. Over the past 52 weeks the share price ranged from $154.50 to $284.50, with a beta of 1.16.
IQVIA Holdings Inc. does not currently pay a dividend.
45 Wall Street analyst ratings cover the stock: 1 Strong Buy, 36 Buy, 7 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, IQVIA Holdings Inc. (IQV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 36.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.67% / 30% · Interest income / Revenue 0.27% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 36.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.49% / 33% · Receivables / Mkt Cap (36m) 7.55% / 49% · Interest income / Revenue 0.27% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 36.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.49% / 33.33% · Receivables / Mkt Cap (24m) 7.55% / 33.33% · Interest income / Revenue 0.27% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 53.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.16% / 33.33% · Receivables / Avg Assets (4Q) 11.7% / 33.33% · Interest income / Revenue 0.27% / 5% | Fail |
| FTSE | Debt / Total Assets 52.7% / 33.33% · (Cash+ST Inv) / Total Assets 7.95% / 33.33% · (Cash+Recv) / Total Assets 18.9% / 33.33% · Interest income / Revenue 0.27% / 5% | Fail |
No. As of September 2026, IQVIA Holdings Inc. (IQV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. IQVIA Holdings Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.27% of each dividend: IQVIA Holdings Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.